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Abstract: Neonatal brain injury is a significant reason of neurodevelopmental abnormalities and long-term neurological impairments.
Hypoxic-ischemic encephalopathy and preterm brain injury, including intraventricular hemorrhage are the most common grounds
of brain injury for full-term and preterm neonates. The prevalence of hypoxic ischemic encephalopathy varies globally, ranging
from 1 to 3.5/1000 live births in high-resource countries and 26/1000 in low-resource countries. Preterm birth’s global incidence is
15 million, a significant reason for infant mortality and morbidity, permanent neurologic problems, and the associated social and
economic burden. The widespread neurodevelopmental effects of neonatal brain injury could have an unfavorable impact on a variety of
aspects of cognitive, linguistic, behavioral, sensory, and motor functions. Brain injury occurs via various mechanisms, including energy
deprivation, excitatory amino acids, mitochondrial dysfunction, reactive oxygen species, and inflammation giving rise to different forms
of cell death. The contribution of microglial activity in neonatal brain injury has widely been underlined by focusing on cell death
mechanisms since the neuronal death pathways during their development are distinct from those in the adult brain. Iron accumulation
and lipid peroxidation cause a relatively novel type of regulated cell death called ferroptosis. Neonates generally have biochemical iron
inequalities, and their antioxidant potential is highly restricted, implying that ferroptosis may be significant in pathologic conditions.
Moreover, inhaled nitric oxide therapy in infants may lead to microglial inflammation via ferroptosis and neuronal injury in the
developing brain. This review article aims to summarize the studies that investigated the association between neonatal brain injury
and iron metabolism, with a particular emphasis on the microglial activity and its application to the inhibition of neonatal brain injury.
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1. Introduction
Neonatal brain injury is a significant reason for
children’s developmental problems and persistent
neurological deficits. Hypoxia and ischemia are central
to the development of brain injury that occurs in fullterm and preterm neonates [1, 2]. Hypoxic-ischemic
encephalopathy (HIE) is a common problem with a global
prevalence ranging from 1 to 3.5/1000 live births in highincome countries and 26/1000 in low-resource countries
[3]. Preterm birth’s global incidence is 15 million and it is a
significant reason for infant mortality and morbidity with
permanent neurologic problems and the associated social
and economic burden [4]. HIE is also associated with
other comorbid neurological disorders such as seizures
and learning, behavioral, visual, cognitive, and motor
disorders [5].

Alarmingly, the incidence of HIE in preterm infants
is higher (4–48 per 1000 preterm neonates), representing
that it accomplishes a major task in the pathogenesis
of preterm brain injury [6, 7]. Currently, there are
no approved therapies for preterm brain injury, and
hypothermia treatment (HT) is the only approved therapy
for term infants in terms of HIE [4, 8]. Still, current HT
practice has decreased HIE-related mortality from 25% to
9% and cerebral palsy (CP) from 20% to 16% [9]. Studies
have revealed that HT did not help all children and that
certain neurodevelopmental problems remain even in
the absence of CP. Thus, further therapies are needed to
improve long-term outcomes [10, 11].
The development of novel therapies for the treatment of
neonatal brain injury strictly requires the identification of
novel cellular pathways, particularly cell death mechanisms
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[12]. Reactive oxygen species (ROS), inflammation,
excitatory amino acids, and mitochondrial dysfunction
are among some of these cellular mechanisms that lead to
brain injury via cell death [11, 13-15]. The neonatal brain
has an increased oxygen consumption, polyunsaturated
fatty acid (PUFA) concentrations, and an insufficient
antioxidant system, making it particularly defenseless
to oxidative damage [16, 17]. Hence, it is fundamental
to focus on the oxidation-based molecular pathways to
understand and deal with brain injury in neonates.
Microglia are the immune cells that act in central
nervous system (CNS) inflammation. They account
for around 10%–15% of all brain cells. Although these
cells are incredibly well-regulated, any abnormalities in
their functions may instigate neurodegeneration and
perinatal and neonatal brain injuries, particularly by cell
death mechanisms in which pyroptosis is dominant [1820]. However, investigating other death mechanisms in
microglia is critically important to fully explore the etiology
of microglia-mediated brain injuries. Neonatal brain injury
leads to different long-term clinical outcomes, including
CP, motor and intellectual impairment, behavioral and
visual problems, learning disorders, seizure, and autism
spectrum disorders [5, 21-24] (Figure 1). This review
aims to assess the literature on neuronal iron metabolism,
lipid peroxidation, and ferroptotic mechanisms, mainly in
microglia that contribute to neonatal brain injuries.
1.1. Iron metabolism, ferroptosis, and neuronal cell
death
As a vital mineral, iron is involved in many metabolic
activities, including electron and oxygen transport, storage,

mitochondrial function, and cellular development. These
biochemical enzymatic reactions are executed by ironcontaining proteins, including hemoglobin and hemecontaining and iron-sulfur enzymes. The imbalance in
the iron metabolism could result in local or systemic
drawbacks via a specific cell death mechanism called
ferroptosis [25, 26].
Ferroptosis is a regulated cell death due to iron
accumulation and lipid peroxidation [25-27]. Despite its
name, ferroptosis is not a kind of cell suicide but rather
a form of cell sabotage that occurs throughout normal
cell activities to adapt to stimulus and physiological
changes [25, 26]. As a result of its dysregulation or
instability, ferroptosis is frequently involved in a variety
of physiological and pathological processes, including
neurotoxicity, cancer, neurodegenerative disorders and
reperfusion injury [26, 27]. Ferroptosis is fundamentally
different from other types of cell death in terms of
evolution, biochemistry, genetics and morphology [25, 26,
28, 29].
At the molecular level, the initial process of ferroptotic
death is mediated by hydroxyl radicals (OH), which are
generated during the Fenton reaction, in which Fe2+ iron is
oxidized to Fe3+, resulting in a highly reactive pro-oxidant
OH radical. The OH radical reacts with PUFAs to produce
lipid radicals. The lipid radical reacts with molecular
oxygen to constitute lipid peroxyl radicals, which spread
the reaction by damaging surrounding lipid molecules,
producing lipid hydroperoxides and more lipid radicals.
These reactions continue until the antioxidant enzyme
glutathione peroxidase 4 (GPX4) catalyzes the reaction by

Figure 1. Flow diagram outlining the clinical outcomes of
microglial ferroptosis resulting from preterm brain injury and
hypoxic ischemic encephalopathy.
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donating hydrogen atoms generated during glutathione
(GSH) synthesis to produce nonradical lipid alcohols
under normal conditions. The enzymatically triggered
process of lipid peroxidation initiates ferroptosis, which
requires phosphatidylethanolamine (PE)-containing
arachidonic acid (AA), one of the major phospholipids that
undergo oxidation. In this process, Acyl-CoA synthetase
long chain family member 4 (ACSL4) acetylates free PUFA
(AA) with coenzyme A to produce AA-CoA, which is
then integrated into the membrane phospholipid PE via
the enzyme lysophosphatidylcholine acyltransferase 3
(LPCAT3). Lipoxygenases (LOXs) then oxidize PE-AA to
form PE-AA-OOH, which promotes ferroptosis [26, 3034]. As revealed by studies aimed at potential mechanisms
of different ferroptosis enhancers, system X, as well as
GPX4 inhibition, could all lead to a decline in GSH levels
and the consecutive release of ROS, particularly as a result
of increased lipid peroxidation levels and ferroptosis [25,
26, 29].
Prior to identifying ferroptosis, deferoxamine (DFO)
was crucial in preventing brain oxidative stress and death.
DFO was already proven to be efficient in the suppression
of CNS cells from death before ferroptosis was discovered
[35, 36]. However, the factor driving this function remains
unknown. Recent studies on ferroptosis could give an
insight into this involvement [30, 35, 37, 38].
Ferroptosis is involved in neuronal cell death generated
by adult ischemia and intraventricular hemorrhage, and
suppression of the ferroptosis protects the neuronal cell
from death [30, 36, 39, 40]. Nevertheless, despite the fact
that there have only been a few studies demonstrating
ferroptosis regarding neonatal brain injury, the evidence
implies that ferroptosis would more likely occur in the
neonatal brain [41-43]. For instance, in a study where
cultured oligodendrocytes were exposed to cysteine-free
conditions to mimic periventricular leukomalacia in vitro,
GSH was depleted, and cell death was increased, which
was also reversed by ferrostatin [32, 44].
Numerous antiferroptotic agents have been discovered
[29, 30, 44-47]. First-generation inhibitors of ferroptosis
include ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1;
[44]. Lipid peroxidation is prevented by those inhibitors,
which react with and donate hydrogen atoms to peroxyl
radicals in lipids [31, 44, 46, 47]. Reduced neurological
impairments, infarct volume, and neuronal death after
a stroke have been shown to be suppressed by inhibition
of ferroptosis by Fer-1 and/or Lip-1, which also reversed
the changes in GPX activity and iron accumulation [30,
47, 48]. Additionally, oligodendrocyte cells have been
protected from cuprizone-induced demyelination by
Fer-1 [41]. These inhibitors are lipid radical scavengers
currently being studied for their role in neurodegenerative
pathology [30, 48, 49]. In parallel, preventing neonatal

brain injury could be one of their applications [26, 27, 30,
39, 42, 44, 48, 50-53].
1.2. Microglia-mediated brain injury, iron metabolism,
and ferroptosis
Neonatal brain injury is presented by a unique
encephalopathy that arises in the early days of life and a
major cause of life-long neurological impairment [54].
There would be numerous molecular reasons for neonatal
brain injury, which are reviewed and emphasized the
involvement of cell death mechanisms [3, 18-20].
Molecular mechanisms behind the association between
microglia, iron metabolism/ferroptosis, and brain injury,
limitedly regarding the developmental stage, have recently
been focused on the literature [55]. The studies underlined
the pro-inflammatory role of ferroptosis in the microglia
[40, 56-61]. However, we regard the contribution of
iron metabolism and ferroptosis to brain injury should
be evaluated in terms of the developmental stage since
the brain development in adults differs from that of the
neonates [16, 30, 62].
In the CNS, macrophages and microglia are crucial for
cell function and immunological protection. CNS-resident
microglia and peripheral macrophages mobilize to act on
an injury or infection. This engagement reflects the most
critical activities of CNS as well as their antiinflammatory
or resolving functions. There is a wide range of features
displayed by macrophages, microglia, and a well-defined
multipattern involving inflammatory/classical (M1)
and resolution/alternative (M2) macrophages/microglia
activation [63].
The iron uptake patterns of M1 and M2 macrophages/
microglia are conceptually distinct. Neonatal brain injury
is hypothesized to arise due to an excess level of iron in the
brain’s most sensitive areas during pregnancy. It is called
neuroinflammation to describe the inflammatory reactions
triggered by the brain’s innate immune system. Even though
brain inflammation shares many characteristics with
peripheral one, it is distinguished by CNS-specialized cells
like neurons, microglia, astrocytes, endothelial cells and
pericytes, which are not found in peripheral inflammation
[15, 18, 19, 49]. In neuroinflammatory situations, the bloodbrain barrier (BBB) is compromised, allowing peripheral
inflammatory cells such as macrophages to move into the
brain. In addition to their effects on cell differentiation,
iron also influences cell homeostasis [18, 49].
Iron could transit the BBB via the transferrin-1
(TFR1), divalent transporter-1 (DMT-1), ferroportin-1
(FPN-1) route, a model similar to that used by cells in
the periphery [64]. Iron is transmitted to the BBB by
FPN, which releases Fe2+ from the cellular membrane of
microvascular endothelial cells, promptly oxidized to Fe3+
by ceruloplasmin, released into the interstitium through
the astrocyte, and afterwards trapped by transferrin.

1417

KELEŞ et al. / Turk J Med Sci
Fe3+ ions in the CNS are linked to small molecules that
astrocytes distribute into the brain [30, 39, 64]. Contrary
to the periphery, CNS encompasses significantly
more nontransferrin-bound iron (NTBI). TFRs are
overexpressed in neurons in their normal state and the
majority of the iron comes from transferrin. Astrocytes
produce DMT-1 and absorb Fe2+ ions, which are present
in the form of NTBI. TFRs facilitate microglia to obtain
transferrin-bound iron (TBI). Neurons and other glial
cells are exposed to NTBI due to higher DMT-1 levels in
an inflammatory setting. Some factors can upset this iron
balance, resulting in an iron deficiency or excess. By the
accumulation of iron in the CNS, iron regulatory protein 1
(IRP1) utilizes the Fe-S complex to gain aconitase activity,
whereas IRP2 is destroyed. As a result, IRPs lose their
affinity for iron responsive elements (IREs), leading to
mRNA breakdown with Fe3+ ions [30, 39, 64].
The iron handling patterns of M1/M2 macrophages are
radically different and surprising. Reduced IRP binding
activity, a lower cytoplasmic labile iron pool (cLIP), lower
levels of TFR1 and FPN1, and more significant amounts
of ferritin heavy (Ferritin-H) found in M1 macrophages.
M1 macrophages are less capable than M2 macrophages
in terms of iron uptake and transfer. M1 macrophages
respond to extracellular iron imbalance or overload with
a limited capacity [51, 65, 66].
Neuroinflammation and iron accumulation, linked by
a complicated network of molecular interactions, form a
toxic circuit that propagates the neurodegenerative process.
Iron stimulates the proinflammatory M1 phenotype in
microglia and macrophages as defined by inducible nitric
oxide synthase (iNOS) production, which is required for
adaptive remodeling of iron homeostasis in M1 microglia/
macrophages [63, 67]. These modifications possibly enable
neuroinflammation to survive, albeit in an environment of
increased oxidative stress, which could be life threatening
to neurons. Additionally, NO can degrade the Fe-S
complex in c-aconitase, assisting IRP1 while driving up
mitochondrial iron reserves and oxidative stress in irondeficient environments, culminating in neuronal death [30,
39, 64]. Importantly, accumulated iron, attributed to hypoxic
conditions at the cellular level, particularly in microglia,
stimulates ROS production, cytokines and oligodendrocyte
apoptosis. Microglia prevents excessive iron accumulation in
immature oligodendrocytes following hypoxic injury [68].
2. Discussions
In our previous study, primary mouse microglia and
astrocytes in culture were exposed to 12 h of hypoxia
with or without mild hypothermic preconditioning. Iron
importer proteins, DMT-1 and TFR1, increased their
mRNA expression in response to hypoxia, and hypothermic
preconditioning maintained the elevation of DMT-1 in
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both glial cell types. Ferroportin expression increased
as a glial cell survival factor after hypoxia. Hypothermic
preconditioning promoted the development in both cell
types, particularly in astrocytes. Following hypothermic
preconditioning, interleukin-10 (Il-10) levels significantly
increased in cells. We demonstrated that hypothermic
preconditioning before hypoxia reduced neurotoxicity and
inhibited the expression of the ferritin light chain, primarily
by modifying transport protein expression. This may be
beneficial by mitigating the iron-related detrimental effects
following hypoxic injury. The fundamental mechanism
that is responsible for therapeutic hypothermia is not yet
fully understood. Hypoxia increased iron overload in the
mixed glial cells and ferritin expression in microglia and
astrocytes via iron transport. We infer that hypothermic
preconditioning may provide a protective strategy during
hypoxia through iron homeostasis. Further research into
in vivo models in terms of the protective mechanism
of therapeutic hypothermia in HIE may give a better
understanding of this in the near future [69].
Following hypoxia-induced brain injury, the
transcription complex of hypoxia-inducible factor 1
subunit alpha (HIF-1α) is activated, resulting in the
activation of multiple genes that enable cells to adjust
to hypoxia and, therefore, recover from cell death. HIF1α regulates TFR1 and DMT1 expressions in neurons,
astrocytes, and microglia [70-72].
In another study, we found that 24-h stimulation of
glyceryl trinitrate (GTN), which serves as a NO donor and
a trigger of iNOS generation, resulted in considerable NO
production in primary mouse microglia, astrocyte, and
meningeal cell cultures. In this work, GTN stimulation
increased the iron absorption in microglia, which was
previously reported. Ferritin light chain expression in
microglia was promoted by GTN, and ferritin heavy chain
expression was stimulated in astrocytes in our study. In
addition to the iron that is taken up by transport proteins,
microglia can obtain iron from phagocytosis from the
environment. As our research has already demonstrated,
microglia were more susceptible to iron deposition than
astrocytes [73].
As a clinical vignette in neonatology, inhaled NO (iNO)
is commonly used in both preterm and term infants in
order to treat primary persistent pulmonary hypertension
resulting from different clinical situations, including sepsis,
hypoxic ischemic encephalopathy, meconium aspiration
syndrome, respiratory distress syndrome, congenital
diaphragmatic hernia, pulmonary hypoplasia and
congenital heart disease [74]. Despite the lack of evidence
of iNO’s efficacy or safety and consensus statements
against its routine utilization in preterm infants, its use
has increased [75]. There is an ongoing discussion on the
neurodevelopmental effect of the iNO in infants and long-
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term neurodevelopment impairment [74-76]. Endogenous
NO affects risk factors in the developing normal and
injured brain [77]. The neuronal isoform NOS-1 induces
either positive benefits through vascular adaptation or
detrimental cellular consequences during ischemia [77, 78].
The influence of exogenous NO on the developing CNS is
highly controversial under normal and stressful situations
[77, 79]. Inhaled NO increases vascular recruitment and
diminishes brain injury only during ischemia but not
reperfusion [77]. We also speculate from our previous
study and current scientific evidence that iNO therapy
in infants may lead to microglial inflammation through
the ferroptosis and contribute to neurodevelopmental
impairment. In line with our hypothesis, NO inhibitors in
the early reperfusion/reoxygenation phase could alleviate
the neonatal brain injury due to hypoxia and ischemia
[52]. These observations highlight the need for further
preclinical and clinical research on the effects of inhaled
NO in neonatal brain injury.
Discovering the molecular route that underlies the
interaction between inflammatory processes and iron
overload will boost the development of novel treatment
methods for interrupting this loop in neonatal brain
injury [39, 43]. Hepcidin therapy, which prevents iron
from penetrating into the CNS, and classical brain iron
chelation are feasible treatment options for these severe
illnesses [30, 32, 48].
It is known that preterm birth is related to an elevated
risk of intracerebral hemorrhage (ICH). Reduced
birth weight and gestational age are associated with
an increased prevalence of ICH. ICH affects 15% of
extremely preterm infants, with more than 50% of all
preterm infants undergoing posthemorrhagic ventricular
dilatation and approximately 30% acquiring long-term
neurodevelopmental sequela [22, 24, 80]. Infants suffering
from ICH are at risk of neurological impairment but no
effective treatment is available. ICH-induced brain injury,
which comprises primary physical damage produced
by the hemorrhage and secondary damage caused by
the action of extremely toxic substances released by the
hemorrhage, is exacerbated by iron formation, resulting in
ventricular dilatation. These components include free iron
and cell-free hemoglobin, which significantly contribute
to ventricular dilatation [81-83]. In addition, the use
of iron-chelator treatment following an ICH is firmly
established, proving the involvement of iron in the onset
and progression of brain damage following an ICH [38].
Significant evidence has been consolidated indicating that
fibrin components, including hemoglobin, fibrinogen,
and iron, are important in developing secondary damage
following an ICH [83-85]. In recent years, neonatologists
have focused on hemoglobin and iron-induced neuronal

toxicity, as hemoglobin and its metabolites are cytotoxic
[86]. They have the potential to create oxidative stress and
inflammation in the body [87]. Heme oxygenase (HO1) degrades hemoglobin in the brain and releases iron,
carbon monoxide and biliverdin into the extracellular
space due to the breakdown of hemoglobin. Following
bleeding, a significant amount of iron is released from
hemoglobin into the interstitial space, resulting in the
generation of free radicals through the Fenton reaction
and, as a result, oxidative destruction to protein, lipids,
and DNA (Figures 2 and 3). The concentrations of NTBI in
the cerebrospinal fluid of preterm with posthemorrhagic
ventricular dilatation were established [88]. Administering
erythrocyte suspension and its breakdown products
causes ventricular dilatation, brain injury, and increased
HO-1 enzyme and ferritin levels in rats, contributing to an
increase in iron overload in the brain [89, 90].
3. Conclusions and future perspectives
For a child to develop to its full potential, programmed
cell death must occur and it occurs more frequently in
newborns than in adults [30, 39, 48]. Moreover, the cellular
iron disparity is noticeable in neonates. Their antioxidant
capacity is insufficient, implying that ferroptosis might
also be significant in infants under pathologic conditions,
despite the relatively small number of studies examining
ferroptosis in neonatal brain injury [18-20, 58].
Neonatal brain injury treatment approaches for the
term and preterm newborns are currently being developed;
therefore, a thorough understanding of their mechanisms
is critical to their success. Ferroptosis in neonatal brain
injury models should be investigated further. In contrast
to non-CNS tissues, iron chelators must transmit the BBB
to reach the CNS parenchyma. Then, they must invade
iron-accumulating cells and retrieve iron from the labile
iron pool and ferritin, and the iron–chelator complex
must depart the cells via the vasculature. Iron chelators
have been reported to be effective in certain neurological
conditions. The mechanism by which these chelators
eliminate iron from the CNS remains to be elucidated and
requires additional research [18,19,42,48].
Even with the therapeutic aim, many clinical
applications could be reviewed considering the potential
microglial involvement, ferroptosis, and possible
clinical and neurodevelopmental outcomes. Common
utilization of iNO in both term and preterm infants may
also be considered an unknown characterized sword.
Comprehensive and precise studies of the molecular
dimensions of cellular iron storage and transfer could
significantly contribute to identification of alternative
strategies for preventing and treating brain injury in
neonates
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Figure 2. Components of ferroptosis pathway are shown
graphically. Cells that are engaged in iron-induced free radical
production (left), as well as GSH/GPX4 dysregulation (in the
middle), have been found to be implicated in this process. To
induce ferroptosis, erastin or RAS-selective lethal 3 (RSL3)
inhibits the amino acid antiporter in system Xc and GPX4,
resulting in lower activity of GPX4. The active site of GPX4
contains selenocysteine. Selenium-tRNA maturation requires
the production of Isopentenyl Pyrophosphate (IPP). The plasma
membrane’s ferroptosis suppressor protein 1 (FSP1) contains
oxidoreductase activity, which lowers coenzyme Q levels and
minimizes L-OOH accumulation. Lipoxygenase requires iron
as a cofactor, which is provided by HO-1, ferritinophagy, and
the labile iron pool (LIP). TFR1: transferrin-1, IREB: Ironresponsive element-binding protein-1 , ACSL4, acyl-CoA
synthetase long-chain family member 4; GPX, glutathione
peroxidase; GSH, glutathione; LOXs, lipoxygenases; LPCAT3,
lysophosphatidylcholine acyltransferase 3; PL, phospholipids;
PL-AA-OOH, lipid hydroperoxides; NCOA4: nuclear receptor
coactivator 4, PUFA : polyunsaturated fatty acid, Nrf-2: nuclear
factor erythroid 2–related factor 2, ATF4: Activated transcription
factors-4, Se: Selenium, CoQ10:Coenzyme Q10, CoQ10H2 : Reduced
coenzyme Q10 , NAD(P)H: nicotinamide adenine dinucleotide
phosphate.

Figure 3. Flow diagram outlining the underlying mechanisms
contributing to neonatal brain injury and potential
prevention mechanisms. Graphical illustration of the main
pathophysiological mechanisms underlying the development
of brain injury in the neonates, namely hypoxia-ischemiareperfusion, hypoxia-hyperoxia, inflammation, hemorrhagic
insults, and PBIs. GSH depletion, glutathione S‐transferase
(GST) deformation, and reduced glutathione peroxidase
(GPX) expression are observed in ferroptosis in neonatal
brain injury. Iron accumulation potentiates inflammation,
ROS, and NO associated with preterm and neonatal brain
injury. Inflammation, excess iron (nontransferrin-bound iron),
intracranial hemorrhage in preterm infants, and hypoxia in
preterm and term infants induce cell death via oxidative stress
and lipid peroxidation. Nitric oxide induces hypoxic ischemic
injury in the neonatal brain via the disruption of neuronal iron
metabolism. Different compounds may also show positive results
in preterm brain injury and hypoxic ischemic encephalopathy,
acting by attenuating different components of ferroptosis. EPO:
Erythropoietin, FER-1: Ferrostatin-1, Lip-1: liproxstatin-1, LOX:
Lipoxygenases, ACSL4: Acyl-CoA synthetase long chain family
member 4, NOS inhibitor: nitric oxide synthase inhibitor.
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